Your browser doesn't support javascript.
loading
Roles of PD-1/PD-L1 immune checkpoint in thyroid diseases / 中华核医学与分子影像杂志
Article in Zh | WPRIM | ID: wpr-993567
Responsible library: WPRO
ABSTRACT
Programmed cell death receptor 1 (PD-1)/PD-1 ligand (PD-L1) maintains immune tolerance of normal tissues and mediates immune escape of tumors. For autoimmune thyroiditis, thyroid follicular epithelial cells inhibit the damage of T cells by up-regulating PD-L1 expression. With the application of immune checkpoint inhibitors (ICIs) in the field of cancer therapy, the incidence of immune-related thyroid disorders caused by ICIs has increased. Thyroid function should be monitored during and after ICIs treatment to promptly diagnose primary and (or) secondary thyroid disorders. The PD-1/PD-L1 signaling directly stimulates thyroid cancer cells, and exerts inhibitory effects on tumor-infiltrating immune cells. Combination of ICIs targeting PD-1/PD-L1 with chemo-radiotherapy or targeted therapy is a promising therapeutic strategy in the treatment of refractory thyroid cancers.
Key words
Full text: 1 Database: WPRIM Language: Zh Journal: Chinese Journal of Nuclear Medicine and Molecular Imaging Year: 2023 Document type: Article
Full text: 1 Database: WPRIM Language: Zh Journal: Chinese Journal of Nuclear Medicine and Molecular Imaging Year: 2023 Document type: Article